Virus therapy takes on tough lung cancer
NCT ID NCT07136285
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment for advanced small cell lung cancer that has stopped responding to standard therapies. The treatment combines an oncolytic virus (Olvi-Vec) with standard chemotherapy drugs. The goal is to see if this combination is safe and can shrink tumors in 27 adult participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai chest hospital
RECRUITINGShanghai, China
-
Zhejiang Provincial People's Hospital
RECRUITINGHangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted drug combo outperform standard chemo for tough lung cancer?
- New drug cocktail aims to shrink tough lung cancers
- New drug cocktail aims at resistant lung cancer
- New drug combo aims to outperform standard care in aggressive lung cancer
- New hope for aggressive lung cancer: drug cocktail plus Low-Dose radiation shows promise
- New combo therapy targets tough lung cancer in early trial